Cross-border venture capital investment in China's life science 2021, by company
In 2021, the Chinese mRNA pharmaceutical company Abogen received a total cross-border venture capital (VC) investment of one billion U.S. dollars. The investors were Temasek, Invesco, Softbank and others. Miaoshou Doctor received the second highest cross-border investment of 697 million U.S. dollars.